Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30091228 | 1.00 | HTR6 (0.55) | HTR6L3MBTL1POLBPPARGRAPGEF4 | |
| SCHEMBL14722247 | 0.90 | HTR6 (0.48) | HTR6L3MBTL1RAPGEF4HTTMAPT | |
| SCHEMBL3260344 | 0.86 | HTR6 (0.65) | HTR6L3MBTL1POLBHTTMEN1 | |
| SCHEMBL29744143 | 0.86 | HTR6 (0.65) | HTR6L3MBTL1POLBHTTMEN1 | |
| SCHEMBL1894102 | 0.85 | HTR6 (0.61) | HTR6L3MBTL1POLBPPARGRAPGEF4 | |
| SCHEMBL31176923 | 0.85 | HTR6 (0.52) | HTR6L3MBTL1POLBPPARGHTT | |
| SCHEMBL18050607 | 0.83 | HTR6 (0.53) | HTR6L3MBTL1POLBPPARGRAPGEF4 | |
| SCHEMBL30669307 | 0.82 | HTR6 (0.50) | HTR6L3MBTL1POLBPPARGRAPGEF4 | |
| SCHEMBL31159451 | 0.82 | HTR6 (0.70) | HTR6L3MBTL1POLBPPARGMEN1 | |
| SCHEMBL3226178 | 0.80 | HTR6 (0.56) | HTR6L3MBTL1POLBPPARGRAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-113880815-B | Indole derivatives, preparation method and application thereof | 中国药科大学 | 2024-03-29 | — | — | CN | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4114529-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-115515685-A | EIF4E inhibitor and application thereof | 皮克医疗公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2022-11-10 | — | — | US | disclosed |
| CN-113880815-A | Indole derivatives and preparation method and application thereof | 中国药科大学 | 2022-01-04 | — | — | CN | disclosed |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-15 | — | — | US | disclosed |
| WO-2004013094-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-12 | — | — | WO | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-0554247-B1 | NEUROPROTECTIVE INDOLONE AND RELATED DERIVATIVES | PFIZER (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994848-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
| US-5498610-A | Neuroprotective indolone and related derivatives | PFIZER INC. (US) | 1996-03-12 | — | — | US | disclosed |
| US-5306723-A | Neuroprotective indolone and related derivatives | PFIZER INC. (US) | 1994-04-26 | — | — | US | disclosed |
| EP-0554247-A1 | NEUROPROTECTIVE INDOLONE AND RELATED DERIVATIVES | PFIZER INC. (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1991017156-A1 | NEUROPROTECTIVE INDOLONE AND RELATED DERIVATIVES | PFIZER INC (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | HTR6 4667/4885L3MBTL1 420/4885POLB 1778/4885 |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | CBR3, TST, CBS | HTR6 2426/4885L3MBTL1 1910/4885POLB 3878/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | HTR6 4667/4885L3MBTL1 420/4885POLB 1778/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | HTR6 4667/4885L3MBTL1 420/4885POLB 1778/4885 |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | HTR6 4667/4885L3MBTL1 420/4885POLB 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.